Worth Watching: Is Buying CoLucid Pharmaceuticals Inc Here a Winning Strategy?

Worth Watching: Is Buying CoLucid Pharmaceuticals Inc Here a Winning Strategy?

The stock of CoLucid Pharmaceuticals Inc (NASDAQ:CLCD) reached all time high today, Nov, 15 and still has $57.23 target or 50.00% above today’s $38.15 share price. This indicates more upside for the $787.46M company. This technical setup was reported by Barchart.com. If the $57.23 PT is reached, the company will be worth $393.73 million more.
Trading stocks at an all time highs is usually a winning strategy. An all time high points to a stock which has the most positive fundamentals ever. Even thought the pullback rate is high, if correct risk management is utilized, investors can trade very well such events. About 40,592 shares traded hands. CoLucid Pharmaceuticals Inc (NASDAQ:CLCD) has risen 460.92% since April 13, 2016 and is uptrending. It has outperformed by 456.99% the S&P500.

CoLucid Pharmaceuticals Inc (NASDAQ:CLCD) Ratings Coverage

Out of 2 analysts covering CoLucid Pharmaceuticals (NASDAQ:CLCD), 1 rate it a “Buy”, 0 “Sell”, while 1 “Hold”. This means 50% are positive. $40 is the highest target while $22 is the lowest. The $31 average target is -18.74% below today’s ($38.15) stock price. CoLucid Pharmaceuticals has been the topic of 4 analyst reports since August 14, 2015 according to StockzIntelligence Inc. William Blair maintained it with “Buy” rating and $22 target price in Friday, August 14 report. Zacks upgraded CoLucid Pharmaceuticals Inc (NASDAQ:CLCD) on Thursday, September 3 to “Hold” rating. The rating was maintained by Stifel Nicolaus with “Buy” on Monday, September 19. The firm has “Buy” rating given on Monday, October 24 by Stifel Nicolaus.

According to Zacks Investment Research, “CoLucid Pharmaceuticals, Inc. is a biopharmaceutical company which develops molecule for the treatment of migraine headaches. The company’s product candidate consists of oral Lasmiditan for the treatment of migraine headache and intravenous lasmiditan for treatment of headache pain, which are in different clinical trial. CoLucid Pharmaceuticals, Inc. is headquartered in Burlington, Massachusetts.”

More recent CoLucid Pharmaceuticals Inc (NASDAQ:CLCD) news were published by: Marketwatch.com which released: “Virtual Stock Exchange” on April 26, 2015. Also Fool.com published the news titled: “Why CoLucid Pharmaceuticals Inc. Soared As Much As 18% on Thursday” on September 15, 2016. Globenewswire.com‘s news article titled: “CoLucid Pharmaceuticals Announces Pricing of Public Offering of Common Stock” with publication date: September 09, 2016 was also an interesting one.

CLCD Company Profile

CoLucid Pharmaceuticals, Inc., incorporated on August 31, 2005, is a Phase III clinical-stage biopharmaceutical company. The Firm is engaged in developing a small molecule for the acute treatment of migraine headaches. The Company’s product candidates address the needs of migraine patients, including those with cardiovascular risk factors or stable cardiovascular disease and those dissatisfied with existing therapies. Lasmiditan, the Company’s lead product candidate, is an oral tablet for the acute treatment of migraine in adults. Lasmiditan selectively targets 5-HT1F receptors expressed in the trigeminal pathway in the central nervous system (CNS). Lasmiditan is designed to penetrate the CNS and block the pathway that contributes to headache pain.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Related posts

Leave a Comment